Author:
Min Sharon,Ingraham Karen,Huang Jianzhong,McCloskey Lynn,Rilling Sarah,Windau Anne,Pizzollo Jason,Butler Deborah,Aubart Kelly,Miller Linda A.,Zalacain Magdalena,Holmes David J.,O'Dwyer Karen
Abstract
ABSTRACTThe continuous emergence of multidrug-resistant pathogenic bacteria is compromising the successful treatment of serious microbial infections. GSK1322322, a novel peptide deformylase (PDF) inhibitor, shows goodin vitroantibacterial activity and has demonstrated safety and efficacy in human proof-of-concept clinical studies.In vitrostudies were performed to determine the frequency of resistance (FoR) to this antimicrobial agent in major pathogens that cause respiratory tract and skin infections. Resistance to GSK1322322 occurred at high frequency through loss-of-function mutations in the formyl-methionyl transferase (FMT) protein inStaphylococcus aureus(4/4 strains) andStreptococcus pyogenes(4/4 strains) and via missense mutations inStreptococcus pneumoniae(6/21 strains), but the mutations were associated with severein vitroand/orin vivofitness costs. The overall FoR to GSK1322322 was very low inHaemophilus influenzae, with only one PDF mutant being identified in one of four strains. No target-based mutants were identified fromS. pyogenes, and only one or no PDF mutants were isolated in three of the fourS. aureusstrains studied. InS. pneumoniae, PDF mutants were isolated from only six of 21 strains tested; an additional 10 strains did not yield colonies on GSK1322322-containing plates. Most of the PDF mutants characterized from those three organisms (35/37 mutants) carried mutations in residues at or in close proximity to one of three highly conserved motifs that are part of the active site of the PDF protein, with 30 of the 35 mutations occurring at position V71 (using theS. pneumoniaenumbering system).
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献